Target and Cell Therapy for Atherosclerosis and CVD

Cardiovascular diseases (CVD) and, in particular, atherosclerosis, remain the main cause of death in the world today. Unfortunately, in most cases, CVD therapy begins after the onset of clinical symptoms and is aimed at eliminating them. In this regard, early pathogenetic therapy for CVD remains an urgent problem in modern science and healthcare. Cell therapy, aimed at eliminating tissue damage underlying the pathogenesis of some pathologies, including CVD, by replacing it with various cells, is of the greatest interest. Currently, cell therapy is the most actively developed and potentially the most effective treatment strategy for CVD associated with atherosclerosis. However, this type of therapy has some limitations. In this review, we have tried to summarize the main targets of cell therapy for CVD and atherosclerosis in particular based on the analysis using the PubMed and Scopus databases up to May 2023.

Automated summary

Cardiovascular diseases (CVD) and atherosclerosis remain the leading cause of death globally. Early pathogenetic therapy for CVD is urgently needed, and cell therapy shows promise as the most effective treatment strategy. However, there are limitations to cell therapy. This review summarizes the main targets of cell therapy for CVD, particularly atherosclerosis, based on analysis of PubMed and Scopus databases up to May 2023.